209 related articles for article (PubMed ID: 23096687)
1. Association of p53 Arg72Pro and MDM2 SNP309 polymorphisms with glioma.
Zhang JN; Yi SH; Zhang XH; Liu XY; Mao Q; Li SQ; Xiong WH; Qiu YM; Chen T; Ge JW
Genet Mol Res; 2012 Oct; 11(4):3618-28. PubMed ID: 23096687
[TBL] [Abstract][Full Text] [Related]
2. Association between MDM2 SNP309, p53 Arg72Pro, and hepatocellular carcinoma risk: A MOOSE-compliant meta-analysis.
Duan X; Li J
Medicine (Baltimore); 2017 Sep; 96(36):e7856. PubMed ID: 28885338
[TBL] [Abstract][Full Text] [Related]
3. MDM2 SNP309, gene-gene interaction, and tumor susceptibility: an updated meta-analysis.
Wan Y; Wu W; Yin Z; Guan P; Zhou B
BMC Cancer; 2011 May; 11():208. PubMed ID: 21619694
[TBL] [Abstract][Full Text] [Related]
4. A functional SNP in the MDM2 promoter, pigmentary phenotypes, and risk of skin cancer.
Nan H; Qureshi AA; Hunter DJ; Han J
Cancer Causes Control; 2009 Mar; 20(2):171-9. PubMed ID: 18814047
[TBL] [Abstract][Full Text] [Related]
5. Clinical implications of the MDM2 SNP309 and p53 Arg72Pro polymorphisms in transitional cell carcinoma of the bladder.
Horikawa Y; Nadaoka J; Saito M; Kumazawa T; Inoue T; Yuasa T; Tsuchiya N; Nishiyama H; Ogawa O; Habuchi T
Oncol Rep; 2008 Jul; 20(1):49-55. PubMed ID: 18575717
[TBL] [Abstract][Full Text] [Related]
6. Effect of TP53 Arg72Pro and MDM2 SNP309 polymorphisms on the risk of high-grade osteosarcoma development and survival.
Toffoli G; Biason P; Russo A; De Mattia E; Cecchin E; Hattinger CM; Pasello M; Alberghini M; Ferrari C; Scotlandi K; Picci P; Serra M
Clin Cancer Res; 2009 May; 15(10):3550-6. PubMed ID: 19451596
[TBL] [Abstract][Full Text] [Related]
7. MDM2 promoter SNP309 is associated with an increased susceptibility to chronic lymphocytic leukemia and correlates with MDM2 mRNA expression in Chinese patients with CLL.
Dong HJ; Fang C; Fan L; Zhu DX; Wang DM; Zhu HY; Zhuang Y; Miao KR; Liu P; Xu W; Li JY
Int J Cancer; 2012 May; 130(9):2054-61. PubMed ID: 21647873
[TBL] [Abstract][Full Text] [Related]
8. Association of breast cancer outcome with status of p53 and MDM2 SNP309.
Boersma BJ; Howe TM; Goodman JE; Yfantis HG; Lee DH; Chanock SJ; Ambs S
J Natl Cancer Inst; 2006 Jul; 98(13):911-9. PubMed ID: 16818855
[TBL] [Abstract][Full Text] [Related]
9. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma.
Hirata H; Hinoda Y; Kikuno N; Kawamoto K; Suehiro Y; Tanaka Y; Dahiya R
Clin Cancer Res; 2007 Jul; 13(14):4123-9. PubMed ID: 17634539
[TBL] [Abstract][Full Text] [Related]
10. MDM2 and P53 polymorphisms contribute together to the risk and survival of prostate cancer.
Xue L; Han X; Liu R; Wang Z; Li H; Chen Q; Zhang P; Wang Z; Chong T
Oncotarget; 2016 May; 7(22):31825-31. PubMed ID: 26025918
[TBL] [Abstract][Full Text] [Related]
11. Distribution and Effects of CDKN2 p16 540 C>G and 580 C>T, and MDM2 SNP309 T>G Polymorphisms in Patients with Primary Brain Tumors.
Kafadar A; Küçükhüseyin Ö; Turan S; Yenilmez EN; Tunoglu S; Zeybek U; Kaynar MY; Kemerdere R; Yaylim I
Anticancer Res; 2015 Jul; 35(7):3933-42. PubMed ID: 26124340
[TBL] [Abstract][Full Text] [Related]
12. TP53 Arg 72Pro and MDM2 SNP309 polymorphisms and colorectal cancer risk: a west Algerian population study.
Abderrahmane R; Louhibi L; Moghtit FZ; Boubekeur A; Benseddik K; Boudjema A; Benrrahal F; Aberkane M; Fodil M; Saidi-Mehtar N
Pathol Oncol Res; 2015 Jul; 21(3):629-35. PubMed ID: 25537146
[TBL] [Abstract][Full Text] [Related]
13. TP53 and MDM2 gene polymorphisms, gene-gene interaction, and hepatocellular carcinoma risk: evidence from an updated meta-analysis.
Peng Q; Lao X; Chen Z; Lai H; Deng Y; Wang J; Mo C; Sui J; Wu J; Zhai L; Yang S; Qin X; Li S
PLoS One; 2013; 8(12):e82773. PubMed ID: 24376578
[TBL] [Abstract][Full Text] [Related]
14. Cigarette smoking, MDM2 SNP309, gene-environment interactions, and lung cancer risk: a meta-analysis.
Bai J; Dai J; Yu H; Shen H; Chen F
J Toxicol Environ Health A; 2009; 72(11-12):677-82. PubMed ID: 19492228
[TBL] [Abstract][Full Text] [Related]
15. Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome.
Bougeard G; Baert-Desurmont S; Tournier I; Vasseur S; Martin C; Brugieres L; Chompret A; Bressac-de Paillerets B; Stoppa-Lyonnet D; Bonaiti-Pellie C; Frebourg T
J Med Genet; 2006 Jun; 43(6):531-3. PubMed ID: 16258005
[TBL] [Abstract][Full Text] [Related]
16. The polymorphisms of P53 codon 72 and MDM2 SNP309 and renal cell carcinoma risk in a low arsenic exposure area.
Huang CY; Su CT; Chu JS; Huang SP; Pu YS; Yang HY; Chung CJ; Wu CC; Hsueh YM
Toxicol Appl Pharmacol; 2011 Dec; 257(3):349-55. PubMed ID: 21982800
[TBL] [Abstract][Full Text] [Related]
17. MDM2 SNP309 polymorphism and colorectal cancer risk: a meta-analysis.
Cao X; Zhang T; Zhao Z; Zhao T
DNA Cell Biol; 2012 Mar; 31(3):355-9. PubMed ID: 21770737
[TBL] [Abstract][Full Text] [Related]
18. Impact of the Mdm2(SNP309-G) allele on a murine model of colorectal cancer.
Zhang X; Pageon L; Post SM
Oncogene; 2015 Aug; 34(33):4412-20. PubMed ID: 25435368
[TBL] [Abstract][Full Text] [Related]
19. Association of p53 codon 72 polymorphism and MDM2 SNP309 with clinical outcome of advanced nonsmall cell lung cancer.
Han JY; Lee GK; Jang DH; Lee SY; Lee JS
Cancer; 2008 Aug; 113(4):799-807. PubMed ID: 18618574
[TBL] [Abstract][Full Text] [Related]
20. MDM2 SNP309 T>G alone or in combination with the TP53 R72P polymorphism does not appear to influence disease expression and age of diagnosis of colorectal cancer in HNPCC patients.
Talseth BA; Meldrum C; Suchy J; Kurzawski G; Lubinski J; Scott RJ
Int J Cancer; 2007 Feb; 120(3):563-5. PubMed ID: 17096342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]